骨疏康颗粒对阿仑膦酸钠治疗骨质疏松症的增效减毒作用研究  

Synergistic and Attenuation Effects of Gushukang Granules on Alendronate in Treatment of Osteoporosis

作　　者：周春[1] 方海姬 谷娜[2] 禹翔[1] 吴玉泉[1] ZHOU Chun;FANG Haiji;GU Na;YU Xiang;WU Yuquan(Dept.of Geriatrics,the 903 Hospital of the Chinese People s Liberation Army Joint Logistics Support Force,Zhejiang Hangzhou 310013,China;Dept.of Pharmacy,the 903 Hospital of the Chinese People s Liberation Army Joint Logistics Support Force,Zhejiang Hangzhou 310013,China)

机构地区：[1]中国人民解放军联勤保障部队第903医院老年医学科,浙江杭州310013 [2]中国人民解放军联勤保障部队第903医院药剂科,浙江杭州310013

出　　处：《中国医院用药评价与分析》2019年第6期679-682,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：浙江省中医药科技计划项目(No.2015ZA179)

摘　　要：目的:探讨骨疏康颗粒对阿仑膦酸钠治疗骨质疏松症的增效减毒作用。方法:选取2013年7月至2016年12月中国人民解放军联勤保障部队第903医院治疗的老年性骨质疏松症患者200例,按随机数字表法分对照组和观察组,每组100例。对照组患者给予阿仑膦酸钠、碳酸钙D 3,观察组患者在对照组基础上加用骨疏康颗粒;均连续服用12个月。比较两组患者的临床疗效、疼痛视觉模拟评分(visual analog score,VAS)、生活质量Oswestry功能障碍指数问卷表(oswestry dability index,ODI)评分、骨密度(BMD)、骨代谢生化指标水平及不良反应发生情况。结果:共194例患者完成研究,其中观察组患者98例,对照组患者96例。观察组患者的总有效率(91.84%,90/98)明显高于对照组(82.29%,79/96),差异有统计学意义( P <0.05)。治疗后,观察组患者的VAS评分、ODI评分明显优于对照组,差异有极显著统计学意义( P <0.01);观察组患者的股骨颈BMD、腰椎BMD优于对照组,但差异无统计学意义( P >0.05);观察组患者的血清碱性磷酸酶、N端中段骨钙素、总Ⅰ型胶原蛋白氨基端延长肽及Ⅰ型胶原降解产物等骨代谢指标水平改善情况均明显优于对照组,差异均有统计学意义( P <0.05);观察组患者血清钙、骨钙素、25羟基维生素D 3及甲状旁腺激素水平有所改善,但与对照组的差异无统计学意义( P >0.05)。两组患者均无严重不良反应发生,观察组患者不良反应发生率明显低于对照组,差异有统计学意义( P <0.05)。结论:骨疏康颗粒对阿仑膦酸钠治疗老年骨质疏松症具有显著的增效减毒作用。OBJECTIVE: To probe into the synergistic and attenuation effects of Gushukang granules on alendronate in treatment of osteoporosis. METHODS: Totally 200 elderly patients with osteoporosis admitted into the 903 Hospital of the Chinese People’s Liberation Army Joint Logistics Support Force from Jul. 2013 to Dec. 2016 were extracted to be divided into the conreol group and the observation group via the random number table, with 100 cases in each group. The control group was given alendronate sodium and calcium carbonate D3, while the observation group was treated with Gushukang granules on the basis of the control group, both groups were continuously administered for 12 months. The clinical efficacy, visual analog score(VAS), quality of life Oswestry disability index(ODI) score, BMD, BMD and the occurrence of adverse drug reactions were compared between two groups. RESULTS: A total of 194 patients completed the study, including 98 patients in the observation group and 96 patients in the control group. The total effective rate of the observation group(91.84%, 90/98) was significantly higher than that of the control group(82.29%, 79/96), and the difference was statistically significant(P<0.05). After treatment, the VAS score and ODI score of the observation group were significantly better than those of the control group, the difference was statistically significant(P<0.01). The BMD of the femoral neck and the BMD of the lumbar spine of the observation group were better than those of the control group, yet the difference was not statistically significant(P>0.05). The serum alkaline phosphatase, N-terminal middle osteocalcin, total type Ⅰ collagen amino terminal prolongation peptide and type Ⅰ collagen degradation products in the observation group were significantly better than those of the control group, and the differences were statistically significant(P<0.05). The serum calcium, osteocalcin, 25-hydroxyvitamin D3 and parathyroid hormone levels were improved in the observation group, but there was no significant

关 键 词：骨疏康颗粒 阿仑膦酸钠 骨质疏松症 

分 类 号：R932[医药卫生—生药学] R969.4[医药卫生—药学]